Prognostic Value of the Lung Immune Prognostic Index in Patients with Untreated Advanced Renal Cell Carcinoma (arcc) Receiving Nivolumab Plus Ipilimumab (N+I) or Sunitinib (SUN) in the CheckMate 214 Trial.
Journal of Clinical Oncology（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined